{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T11:48:03Z","timestamp":1795088883350,"version":"4.10.2"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T00:00:00Z","timestamp":1748649600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T00:00:00Z","timestamp":1748649600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key R&D Program of China","doi-asserted-by":"crossref","award":["2022YFC2703901"],"award-info":[{"award-number":["2022YFC2703901"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U20A20341"],"award-info":[{"award-number":["U20A20341"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170084"],"award-info":[{"award-number":["82170084"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Sciences","award":["CIFMS 2021-I2M-1-003"],"award-info":[{"award-number":["CIFMS 2021-I2M-1-003"]}]},{"name":"National High Level Hospital Clinical Research Funding","award":["2022-PUMCH-B-107"],"award-info":[{"award-number":["2022-PUMCH-B-107"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Lymphangioleiomyomatosis (LAM) is a rare, low-grade neoplasm. Abnormal activation of the mammalian target of rapamycin (mTOR) pathway plays a critical role in LAM pathogenesis by promoting cell proliferation, which may increase susceptibility to malignancies in these patients. However, owing to the rarity of LAM, comprehensive data on the risk of malignancy in this population are limited.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We retrospectively analyzed 849 LAM patients who participated in the LAM-China Registry Study at Peking Union Medical College Hospital. We collected medical records of patients with malignant tumors and estimated the incidence of malignancy in the LAM-China cohort.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A total of 849 patients were included in our research, of whom 760 were sporadic LAM and 89 had tuberous sclerosis complex-associated LAM. Thirty-one patients (3.65%) had a history of malignancy. More than 80% of LAM and malignant tumors developed successively within 5 years, with a median time interval of 1.5 years. Eighteen patients who were diagnosed with malignancy after diagnosis of LAM were included in the incidence calculation. The three most prevalent cancers were thyroid cancer (<jats:italic>n<\/jats:italic>\u2009=\u20095), breast cancer (<jats:italic>n<\/jats:italic>\u2009=\u20094) and ovarian cancer (<jats:italic>n<\/jats:italic>\u2009=\u20093). Except for lung cancer, the SIRs for all other cancers mentioned in the present study were significantly increased: thyroid cancer (SIR\u2009=\u200910.87, 95% CI 3.53\u201325.37), breast cancer (SIR\u2009=\u20095.95, 95% CI 1.62\u201315.24), and ovarian cancer (SIR\u2009=\u200924.54, 95% CI 5.07\u201371.86). After standardization by age, the SIR for malignancy in our cohort was 3.20 (95% CI 1.89\u20135.05, <jats:italic>p<\/jats:italic>\u2009=\u20090.00003). However, this elevated risk of malignancy appeared to be confined to younger age groups. Among individuals aged over 50 years, there was no statistically significant difference in the incidence of malignancy between LAM patients and the reference population.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>The risk of malignant tumors is significantly increased in LAM patients than that in the reference population. Thyroid cancer, breast cancer, and ovarian cancer were the three most prevalent malignancies in our cohort. Each type of cancer that appeared in the cohort presented a relatively high incidence, except for lung cancer.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13023-025-03834-w","type":"journal-article","created":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T16:16:28Z","timestamp":1748708188000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Increased malignancy risk in patients with lymphangioleiomyomatosis: findings from a Chinese cohort"],"prefix":"10.1186","volume":"20","author":[{"given":"Xiaoxin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongsheng","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanghang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junya","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiapeng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinhe","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7662-531X","authenticated-orcid":false,"given":"Kai-Feng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,31]]},"reference":[{"issue":"12","key":"3834_CR1","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1164\/rccm.201205-0848OE","volume":"186","author":"FX McCormack","year":"2012","unstructured":"McCormack FX, Travis WD, Colby TV, Henske EP, Moss J, Lymphangioleiomyomatosis. Am J Respir Crit Care Med. 2012;186(12):1210\u20132.","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"3834_CR2","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1164\/rccm.201607-1384ST","volume":"194","author":"FX McCormack","year":"2016","unstructured":"McCormack FX, Gupta N, Finlay GR, Young LR, Taveira-DaSilva AM, Glasgow CG, et al. Official American thoracic society\/japanese respiratory society clinical practice guidelines: Lymphangioleiomyomatosis diagnosis and management. Am J Respir Crit Care Med. 2016;194(6):748\u201361.","journal-title":"Am J Respir Crit Care Med"},{"key":"3834_CR3","doi-asserted-by":"crossref","unstructured":"McCarthy C. Lymphangioleiomyomatosis: pathogenesis, clinical features, diagnosis, and management. Lancet Respiratory Med. 2021;1313\u201327.","DOI":"10.1016\/S2213-2600(21)00228-9"},{"issue":"11","key":"3834_CR4","doi-asserted-by":"publisher","first-page":"6085","DOI":"10.1073\/pnas.97.11.6085","volume":"97","author":"T Carsillo","year":"2000","unstructured":"Carsillo T, Astrinidis A, Henske EP. Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary Lymphangioleiomyomatosis. Proc Natl Acad Sci USA. 2000;97(11):6085\u201390.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"3834_CR5","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1086\/301804","volume":"62","author":"TA Smolarek","year":"1998","unstructured":"Smolarek TA, Wessner LL, McCormack FX, Mylet JC, Menon AG, Henske EP. Evidence that lymphangiomyomatosis is caused by TSC2 mutations: chromosome 16p13 loss of heterozygosity in angiomyolipomas and lymph nodes from women with lymphangiomyomatosis. Am J Hum Genet. 1998;62(4):810\u20135.","journal-title":"Am J Hum Genet"},{"issue":"9","key":"3834_CR6","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.cell.2017.02.004","volume":"168","author":"RA Saxton","year":"2017","unstructured":"Saxton RA. mTOR signaling in growth, metabolism, and disease. Cell. 2017;168(9):960\u201376.","journal-title":"Cell"},{"issue":"1","key":"3834_CR7","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s10549-016-3737-8","volume":"156","author":"O Nu\u00f1ez","year":"2016","unstructured":"Nu\u00f1ez O, Rom\u00e1n A, Johnson SR, Inoue Y, Hirose M, Casanova \u00c1, et al. Study of breast cancer incidence in patients of Lymphangioleiomyomatosis. Breast Cancer Res Treat. 2016;156(1):195\u2013201.","journal-title":"Breast Cancer Res Treat"},{"key":"3834_CR8","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.canep.2019.06.004","volume":"61","author":"O Nu\u00f1ez","year":"2019","unstructured":"Nu\u00f1ez O, Baldi BG, Radzikowska E, Carvalho CRR, Herranz C, Sobiecka M, et al. Risk of breast cancer in patients with Lymphangioleiomyomatosis. Cancer Epidemiol. 2019;61:154\u20136.","journal-title":"Cancer Epidemiol"},{"issue":"9","key":"3834_CR9","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1111\/resp.14724","volume":"29","author":"M Torasawa","year":"2024","unstructured":"Torasawa M, Shukuya T, Uemura K, Hayashi T, Ueno T, Kohsaka S, et al. Lymphangioleiomyomatosis as a potent lung cancer risk factor: insights from a Japanese large cohort study. Respirology. 2024;29(9):815\u201324.","journal-title":"Respirology"},{"issue":"1","key":"3834_CR10","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1183\/09031936.00076209","volume":"35","author":"SR Johnson","year":"2010","unstructured":"Johnson SR, Cordier JF, Lazor R, Cottin V, Costabel U, Harari S, et al. European respiratory society guidelines for the diagnosis and management of Lymphangioleiomyomatosis. Eur Respir J. 2010;35(1):14\u201326.","journal-title":"Eur Respir J"},{"key":"3834_CR11","unstructured":"National Central Cancer Registry, editor. CHINA CANCER REGISTRY ANNUAL REPORT 2021. Bei Jing: People\u2019s Medical Publishing House. 2023. 318 p."},{"issue":"4","key":"3834_CR12","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1093\/biomet\/26.4.404","volume":"26","author":"CJ Clopper","year":"1934","unstructured":"Clopper CJ, Pearson ES, THE USE OF CONFIDENCE OR FIDUCIAL, LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL. Biometrika. 1934;26(4):404\u201313.","journal-title":"Biometrika"},{"issue":"4","key":"3834_CR13","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1136\/jech.2007.063560","volume":"62","author":"R Supramaniam","year":"2008","unstructured":"Supramaniam R. New malignancies among cancer survivors: SEER cancer registries, 1973\u20132000. J Epidemiol Community Health. 2008;62(4):375\u20136.","journal-title":"J Epidemiol Community Health"},{"key":"3834_CR14","unstructured":"Engels EA, Pfeiffer RM Jr, Kasiske JFF, Israni BL, Snyder AK. JJ, Spectrum of Cancer Risk Among US Solid Organ Transplant Recipients."},{"key":"3834_CR15","doi-asserted-by":"crossref","unstructured":"Sargen MR, Cahoon EK, Yu KJ, Madeleine MM, Zeng Y, Rees JR et al. Spectrum of nonkeratinocyte skin Cancer risk among solid organ transplant recipients in the US. 2022.","DOI":"10.1001\/jamadermatol.2022.0036"},{"issue":"nov24 1","key":"3834_CR16","doi-asserted-by":"publisher","first-page":"g6679","DOI":"10.1136\/bmj.g6679","volume":"349","author":"GA Knoll","year":"2014","unstructured":"Knoll GA, Kokolo MB, Mallick R, Beck A, Buenaventura CD, Ducharme R, et al. Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data. BMJ. 2014;349(nov24 1):g6679\u20136679.","journal-title":"BMJ"},{"issue":"1","key":"3834_CR17","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/ijd.14549","volume":"59","author":"K Phan","year":"2020","unstructured":"Phan K, Moloney FJ, Hogarty DT, Lenane P, McColl D, Yazdabadi A. Mammalian target of Rapamycin (mTOR) inhibitors and skin cancer risk in nonrenal solid organ transplant recipients: systematic review and meta-analysis. Int J Dermatology. 2020;59(1):91\u20138.","journal-title":"Int J Dermatology"},{"issue":"4","key":"3834_CR18","first-page":"480","volume":"45","author":"MR de F\u00e1zio","year":"2023","unstructured":"de F\u00e1zio MR, Cristelli MP, Tomimori J, Koga CE, Ogawa MM, Beneventi GT, et al. Use of sirolimus as an adjuvant therapy for kidney transplant recipients with high-risk cutaneous squamous cell carcinomas: a prospective non-randomized controlled study. J Bras Nefrol. 2023;45(4):480\u20137.","journal-title":"J Bras Nefrol"},{"key":"3834_CR19","doi-asserted-by":"publisher","first-page":"096368972413094","DOI":"10.1177\/09636897241309412","volume":"34","author":"C Orr","year":"2025","unstructured":"Orr C, Stratton J, El-Shahawy M, Forouhar E, Peng A, Singh G, et al. Impact of tacrolimus, sirolimus, age, and body mass index on the occurrence of skin Cancer and islet dysfunction after transplantation. Cell Transpl. 2025;34:09636897241309412.","journal-title":"Cell Transpl"},{"issue":"3","key":"3834_CR20","doi-asserted-by":"publisher","first-page":"e14207","DOI":"10.1111\/ctr.14207","volume":"35","author":"J Pr\u00e9terre","year":"2021","unstructured":"Pr\u00e9terre J, Visentin J, Saint Cricq M, Kaminski H, Del Bello A, Prezelin-Reydit M, et al. Comparison of two strategies based on mammalian target of Rapamycin inhibitors in secondary prevention of non\u2010melanoma skin cancer after kidney transplantation, a pilot study. Clin Transplant. 2021;35(3):e14207.","journal-title":"Clin Transplant"},{"issue":"1","key":"3834_CR21","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1080\/0886022X.2020.1785499","volume":"42","author":"SL Murray","year":"2020","unstructured":"Murray SL, Daly FE, O\u2019Kelly P, O\u2019Leary E, Deady S, O\u2019Neill JP, et al. The impact of switching to mTOR inhibitor-based immunosuppression on long-term non-melanoma skin cancer incidence and renal function in kidney and liver transplant recipients. Ren Fail. 2020;42(1):607\u201312.","journal-title":"Ren Fail"},{"issue":"11","key":"3834_CR22","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.3349\/ymj.2022.0247","volume":"63","author":"HS Lee","year":"2022","unstructured":"Lee HS, Kim JY, Ro SW, Kim MS, Kim H, Joo DJ. Antitumor effect of Low-Dose of Rapamycin in a Transgenic mouse model of liver Cancer. Yonsei Med J. 2022;63(11):1007\u201315.","journal-title":"Yonsei Med J"},{"issue":"5","key":"3834_CR23","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s10552-008-9260-4","volume":"20","author":"BA Kilfoy","year":"2009","unstructured":"Kilfoy BA, Zheng T, Holford TR, Han X, Ward MH, Sjodin A, et al. International patterns and trends in thyroid cancer incidence, 1973\u20132002. Cancer Causes Control. 2009;20(5):525\u201331.","journal-title":"Cancer Causes Control"},{"issue":"6","key":"3834_CR24","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424.","journal-title":"CA Cancer J Clin"},{"key":"3834_CR25","unstructured":"TAN M, YANG S, LIU Z, LIU Y, Xu X. Advances in etiology of high incidence of thyroid Cancer in women. Med J Peking Union Med Coll Hosp. 2024;15(6)."},{"key":"3834_CR26","doi-asserted-by":"publisher","first-page":"110776","DOI":"10.1016\/j.envres.2021.110776","volume":"195","author":"T Qi","year":"2021","unstructured":"Qi T, Huang Y, Li S, Ying Q, Jiang Z, Ma L, et al. Associations of age at natural menopause and occupations in Chinese female workers: A cross-sectional study. Environ Res. 2021;195:110776.","journal-title":"Environ Res"},{"issue":"1","key":"3834_CR27","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1089\/lrb.2009.0020","volume":"8","author":"J Yu","year":"2010","unstructured":"Yu J, Henske EP. mTOR activation, lymphangiogenesis, and Estrogen-Mediated cell survival: the perfect storm of Pro-Metastatic factors in LAM pathogenesis. Lymphatic Res Biology. 2010;8(1):43\u20139.","journal-title":"Lymphatic Res Biology"},{"issue":"37","key":"3834_CR28","doi-asserted-by":"publisher","first-page":"14960","DOI":"10.1073\/pnas.1309110110","volume":"110","author":"X Gu","year":"2013","unstructured":"Gu X, Yu JJ, Ilter D, Blenis N, Henske EP, Blenis J. Integration of mTOR and estrogen\u2013ERK2 signaling in Lymphangioleiomyomatosis pathogenesis. Proc Natl Acad Sci USA. 2013;110(37):14960\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3834_CR29","doi-asserted-by":"crossref","unstructured":"Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, et al. Influence of Estrogen plus progestin on breast Cancer and mammography in healthy postmenopausal women: the women\u2019s health initiative randomized trial. Obstet Gynecol Surv. 2003;58(11):735\u20137.","DOI":"10.1097\/01.OGX.0000093674.44946.D6"},{"issue":"4","key":"3834_CR30","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1001\/jama.2020.9482","volume":"324","author":"RT Chlebowski","year":"2020","unstructured":"Chlebowski RT, Anderson GL, Aragaki AK, Manson JE, Stefanick ML, Pan K, et al. Association of menopausal hormone therapy with breast Cancer incidence and mortality during Long-term Follow-up of the women\u2019s health initiative randomized clinical trials. JAMA. 2020;324(4):369.","journal-title":"JAMA"},{"issue":"7","key":"3834_CR31","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1097\/GME.0000000000002028","volume":"29","author":"The 2022 hormone therapy position statement of The North American","year":"2022","unstructured":"The 2022 hormone therapy position statement of The North American. Menopause Soc Menopause. 2022;29(7):767\u201394.","journal-title":"Menopause Soc Menopause"},{"key":"3834_CR32","doi-asserted-by":"crossref","unstructured":"Baber RJ, Panay N, Fenton A. 2016 IMS Recommendations on women\u2019s midlife health and menopause hormone therapy. Climacteric. 2016;19(2):109\u201350.","DOI":"10.3109\/13697137.2015.1129166"},{"issue":"2","key":"3834_CR33","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/0029-7844(94)00383-O","volume":"85","author":"D Grady","year":"1995","unstructured":"Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol. 1995;85(2):304\u201313.","journal-title":"Obstet Gynecol"},{"issue":"5","key":"3834_CR34","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1001\/jama.1996.03530290040035","volume":"275","author":"Effects of hormone replacement therapy on endometrial histology in postmenopausal women","year":"1996","unstructured":"Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The postmenopausal estrogen\/progestin interventions (PEPI) trial. The writing group for the PEPI trial. JAMA. 1996;275(5):370\u20135.","journal-title":"JAMA"},{"issue":"9980","key":"3834_CR35","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/S0140-6736(14)61687-1","volume":"385","author":"Collaborative Group on Epidemiological Studies of Ovarian Cancer","year":"2015","unstructured":"Collaborative Group on Epidemiological Studies of Ovarian Cancer. Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. Lancet. 2015;385(9980):1835\u201342.","journal-title":"Lancet"},{"issue":"24","key":"3834_CR36","doi-asserted-by":"publisher","first-page":"2888","DOI":"10.1200\/JCO.2016.66.8178","volume":"34","author":"N Wentzensen","year":"2016","unstructured":"Wentzensen N, Poole EM, Trabert B, White E, Arslan AA, Patel AV, et al. Ovarian Cancer risk factors by histologic subtype: an analysis from the ovarian Cancer cohort consortium. JCO. 2016;34(24):2888\u201398.","journal-title":"JCO"},{"issue":"4","key":"3834_CR37","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1164\/rccm.202310-1736LE","volume":"209","author":"E Lynn","year":"2024","unstructured":"Lynn E, Forde SH, Franciosi AN, Bendstrup E, Veltkamp M, Wind AE, et al. Updated prevalence of Lymphangioleiomyomatosis in Europe. Am J Respir Crit Care Med. 2024;209(4):456\u20139.","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"3834_CR38","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1089\/thy.2013.0045","volume":"23","author":"LGT Morris","year":"2013","unstructured":"Morris LGT, Sikora AG, Tosteson TD, Davies L. The increasing incidence of thyroid cancer: the influence of access to care. Thyroid. 2013;23(7):885\u201391.","journal-title":"Thyroid"},{"issue":"1","key":"3834_CR39","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.chest.2022.08.2207","volume":"163","author":"M Wang","year":"2023","unstructured":"Wang M, Lin S, He N, Yang C, Zhang R, Liu X, et al. The introduction of Low-Dose CT imaging and lung Cancer overdiagnosis in Chinese women. Chest. 2023;163(1):239\u201350.","journal-title":"Chest"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03834-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-03834-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03834-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T16:16:30Z","timestamp":1748708190000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-025-03834-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,31]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3834"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-03834-w","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,31]]},"assertion":[{"value":"10 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study is a subsidiary study of the LAM-Chian Registry Study. LAM-China was approved by the ethics committee of the Peking Union Medical College Hospital in Beijing (reference number JS-1323).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Signed informed consent was obtained from all participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The abstract of this article has been accepted for POSTER presentation at the 2025 ATS International Conference. Currently, the relevant DOI and conference paper links have not been assigned.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statement"}}],"article-number":"263"}}